SCHEMBL4354248

SCHEMBL4354248

COC(=O)c1c(NC(=O)c2ccc(F)cc2)cnn1C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.54
CYP2C19 P33261 2/20 0.54
CYP2D6 P10635 1/20 0.54
TSHR P16473 1/20 0.54
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
ATM Q13315 1/20 0.52
KDM4E B2RXH2 4/20 0.50
CNR2 P34972 1/20 0.50
KMT2A Q03164 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
GAA P10253 1/20 0.48
MEN1 O00255 1/20 0.48
ALDH1A1 P00352 1/20 0.47
HPGD P15428 1/20 0.47
F2 P00734 1/20 0.47
MAPT P10636 1/20 0.47
LMNA P02545 3/20 0.47
HTT P42858 1/20 0.45
GFER P55789 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4201013 0.84 SMN1; SMN2 (0.48) CYP1A2CYP2C19CYP2D6TSHRNPC1
SCHEMBL4354244 0.81 BPTF (0.56) CYP1A2CYP2C19NPC1RAB9AATM
SCHEMBL30908549 0.77 CNR2 (0.59) CYP1A2CYP2C19KDM4ECNR2KMT2A
SCHEMBL18255876 0.75 CNR2 (0.54) CYP1A2CYP2C19KDM4ECNR2KMT2A
SCHEMBL27409311 0.75 CNR2 (0.56) CYP1A2CYP2C19KDM4ECNR2KMT2A
SCHEMBL1881753 0.73 CNR2 (0.55) CYP1A2CYP2C19KDM4ECNR2KMT2A
SCHEMBL27409318 0.72 CNR2 (0.54) CYP1A2CYP2C19KDM4ECNR2KMT2A
SCHEMBL24485756 0.72 CNR2 (0.46) CYP1A2CYP2C19KDM4ECNR2KMT2A
SCHEMBL24255818 0.71 CNR2 (0.53) CYP1A2CYP2C19KDM4ECNR2KMT2A
SCHEMBL14747480 0.71 ALDH1A1 (0.54) CYP1A2TSHRNPC1RAB9AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
WO-2009026241-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-26 WO disclosed
WO-2009026241-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 GPBAR1, GPR119, GRK5 CYP1A2 2694/4885CYP2C19 3288/4885CYP2D6 2526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.